GlassScriptPhysician profile
Tracy S Leong
NPI 1003133216
$5,307.57
in general payments reported to CMS, 2019-2025
26 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $867 · 2021: $704 · 2022: $659 · 2023: $998 · 2024: $687 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $700.89 | 2019-2024 | |
| Pfizer INC. | $658.25 | 2019-2024 | |
| Genzyme Corporation | $547.43 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $390.29 | 2019-2024 | Ilumya, Winlevi |
| Leo Pharma INC. | $368.43 | 2020-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $339.16 | 2019-2024 | Zepbound, Taltz |
| Janssen Biotech, INC. | $183.63 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $173.26 | 2019-2023 | Dupixent |
| Amgen INC. | $157.91 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $144.88 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $97.55 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.62 | 2019 | |
| Ucb, INC. | $79.30 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $68.86 | 2021-2025 | Opzelura |
| Celgene Corporation | $65.10 | 2019 | |
| Prugen, INC. Pharmaceuticals | $60.15 | 2019-2020 | |
| Biofrontera INC. | $44.39 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.97 | 2024 | Spevigo |
| Dermira, INC. | $23.89 | 2020 | |
| Boston Scientific Corporation | $19.91 | 2024 | |
| Epi Health, LLC | $19.02 | 2020 | |
| Verrica Pharmaceuticals INC. | $19.01 | 2024 | Ycanth |
| Integra Lifesciences Corporation | $14.16 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Leong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.